Pioneer in phage-based diagnostics

01359 231856

Twitter Youtube Linkedin Envelope
  • Home
  • About
    • About PBD Biotech
    • Leadership
    • Blog
  • Latest
    • Press releases
    • In the news
    • Events
  • Actiphage TB
    • What is Actiphage TB?
    • Unique role in TB testing
    • Supporting test and treat campaigns
    • Clinical studies
  • Lab Support
    • Laboratory Support
    • Solutions for laboratory developed tests
    • Actiphage assay workflow
    • Instructions for use of Actiphage
  • TB Drug Research
    • TB drug research
    • Research Use Only
    • Biomarker for TB prevention
  • Contact
    • Contacting us
    • Partnerships and collaborations
Menu
  • Home
  • About
    • About PBD Biotech
    • Leadership
    • Blog
  • Latest
    • Press releases
    • In the news
    • Events
  • Actiphage TB
    • What is Actiphage TB?
    • Unique role in TB testing
    • Supporting test and treat campaigns
    • Clinical studies
  • Lab Support
    • Laboratory Support
    • Solutions for laboratory developed tests
    • Actiphage assay workflow
    • Instructions for use of Actiphage
  • TB Drug Research
    • TB drug research
    • Research Use Only
    • Biomarker for TB prevention
  • Contact
    • Contacting us
    • Partnerships and collaborations

Actiphage clinical studies

Groundbreaking science – clinical studies have shown promise in predicting which individuals with latent tuberculosis might progress to active disease.

Actiphage detects mycobacterium tuberculosis in latent TB patients associated with progression to active tuberculosis

  • Actiphage provided the first concordant evidence in humans to detect incipient TB in early infection.
  • Actiphage had high correlation of 73% for positive test results in active pulmonary TB (PTB) patients.
  • Actiphage found 17% QFT positive pts to be Incipient, with 2 patients progressing to active TB after 7 months.
  • Actiphage results in remaining LTBI cohort (15), healthy controls (28) 100% negative.
  • Actiphage had a sensitivity of 73% and specificity of 100% in symptomatic patients with suspected PTB.
  • Actiphage had a specificity of 94% for all patients, with no change in sensitivity.

Verma, R. et al, ‘A novel high sensitivity bacteriophage-based assay identifies low level M. tuberculosis bacteraemia in immunocompetent patients with active and incipient TB’, Clinical Infectious Diseases, ciz548 – view the paper

Actiphage detects mycobacterium tuberculosis DNA associated with progression in incipient tuberculosis patients

  • First study to isolate Mtb in LTBI representing uncontrolled infection, distinguishing LTBI from incipient TB.
  • There was a significant association of Actiphage detection of Mtb DNA with imaging and microbiological results of incipient TB.
  • Screening with Actiphage had high sensitivity and specificity for stratifying TB risk in recently exposed household contacts.

Jee Whang Kim et al, A novel bacteriophage-based assay stratifies tuberculosis risk in recent household contacts of pulmonary tuberculosis: A prospective observational cohort study – view the paper

Presented at 32nd European Congress of Clinical Microbiology & Infectious Diseases April 2022

Ongoing Actiphage clinical studies

  • High TB burden tuberculosis settings. Studies in South Africa and Zambia and planned study with R2D2 in Philippines. Visit the R2D2 website here.
  • Genotyping drug-resistant mycobacterium tuberculosis. Project to evaluate Actiphage in conjunction with sequencing to determine genotypes associated with drug resistance on a variety of isolates of M. tuberculosis.
  • Further trials are underway in the UK and internationally.

Phage-based diagnostic research

  • Evidence of Mycobacterium tuberculosis complex bacteraemia in intradermal skin test positive cattle detected using phage-RPA

Convery T., Rees C. et al, ‘Evidence of Mycobacterium tuberculosis complex bacteraemia in intradermal skin test positive cattle detected using phage-RPA‘, Virulence (2016), 7 (7), 779-788 – view the paper.

developers of phage-based diagnostics

Contact Us
BIVDA member 2023

Registered Company Address
Grosvenor St Paul’s
Grosvenor House
11 St Paul’s Square
Birmingham
B3 1RB
United Kingdom

T: 01359 231856
info@pbdbio.com

Privacy and cookies policy

© 2022 PBD Biotech Ltd

design: out of house

  • Follow Us!